These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. van Rhee F; Hochhaus A; Lin F; Melo JV; Goldman JM; Cross NC Blood; 1996 Jun; 87(12):5213-7. PubMed ID: 8652835 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954 [TBL] [Abstract][Full Text] [Related]
6. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization. Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246 [TBL] [Abstract][Full Text] [Related]
7. Fas-mediated modulation of Bcr/Abl in chronic myelogenous leukemia results in differential effects on apoptosis. Selleri C; Maciejewski JP; Pane F; Luciano L; Raiola AM; Mostarda I; Salvatore F; Rotoli B Blood; 1998 Aug; 92(3):981-9. PubMed ID: 9680367 [TBL] [Abstract][Full Text] [Related]
8. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia]. Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985 [TBL] [Abstract][Full Text] [Related]
9. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis. Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866 [TBL] [Abstract][Full Text] [Related]
10. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance. Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282 [TBL] [Abstract][Full Text] [Related]
11. Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene. Snyder DS; Wu Y; McMahon R; Yu L; Rossi JJ; Forman SJ Biol Blood Marrow Transplant; 1997 Oct; 3(4):179-86. PubMed ID: 9360779 [TBL] [Abstract][Full Text] [Related]
13. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536 [TBL] [Abstract][Full Text] [Related]
14. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia. Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222 [TBL] [Abstract][Full Text] [Related]
15. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice. Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208 [TBL] [Abstract][Full Text] [Related]
16. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice. Voncken JW; Kaartinen V; Pattengale PK; Germeraad WT; Groffen J; Heisterkamp N Blood; 1995 Dec; 86(12):4603-11. PubMed ID: 8541551 [TBL] [Abstract][Full Text] [Related]
17. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model. Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059 [TBL] [Abstract][Full Text] [Related]
18. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478 [TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of an immature human megakaryoblastic cell line, MEG-A2. Abe A; Emi N; Kato H; Adachi K; Murate T; Saga S; Ogura M; Kojima T; Tanimoto M; Morishita N Leukemia; 1995 Feb; 9(2):341-9. PubMed ID: 7869773 [TBL] [Abstract][Full Text] [Related]
20. [Construction of retrovirus vector of bcr/abl mRNA cleaving ribozyme gene and its effects on K562 cells]. Wu Y; Chen Y; Hu J Zhonghua Xue Ye Xue Za Zhi; 1998 Dec; 19(12):623-6. PubMed ID: 11263328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]